Compare Datadog Inc (DDOG) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Heron Therapeutics Inc — how do they compare? Datadog Inc trades at $275.15 (market cap $97.43B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Datadog Inc is far larger — about 1315.9× Heron Therapeutics Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Heron Therapeutics Inc for 35 Days on average.
| DDOG | HRTX | |
|---|---|---|
Market Cap | $97.43B | $74.04M |
Volume | 1,586,926 | 3,668,095 |
Sector | Technology | Health |
52-Week High | $288.15 | $1.49 |
52-Week Low | $102.62 | $0.27 |
Typical Hold Time | 76 Days | 35 Days |
Enterprise Value | $93.72B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $273.8, down 1.6% on the day, yet maintains a bullish technical stance with strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margins are volatile. Positive sentiment is fueled by AI-driven demand and global expansion, as highlighted in recent financial media.
The outlook is cautiously optimistic given high valuation multiples (P/E 542.68) and negative net cash flow, but strong revenue growth and a dominant buy rating consensus (83.34%) suggest upside to the $276.10 price target. Key risks include competitive pressures and reliance on enterprise cloud spending cycles.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
